Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation - PubMed (original) (raw)
. 1994 May;41(3-4):164-70.
doi: 10.1007/BF02001911.
Affiliations
- PMID: 7942324
- DOI: 10.1007/BF02001911
Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation
K U Weithmann et al. Agents Actions. 1994 May.
Abstract
Leflunomide exerts its effects primarily via the immunomodulating and antiphlogistic activities of its major metabolite A 77 1726. Our investigation in several eicosanoid forming systems revealed that in human white blood cells the metabolite did not cause any alteration on Ca-ionophore stimulated metabolism of membrane bound arachidonic acid to cis-, trans- and epi-LTB4. Thus, the involved enzyme systems phospholipase A2, 5-lipoxygenase and LTA4-hydrolase can be ruled out as a target of the drug. However, in several cellular systems the drug weakly inhibited the generation of 5-HETE and LTB4 from exogenous arachidonic acid, possibly by interfering with the exogenous substrate's access to the 5-lipoxygenase. In order to get information about the cyclooxygenase (COX-2) which is inducible in human PMNL by inflammatory mediators via de novo protein biosynthesis, we activated the cells with LPS for 18 h. A 77 1726 and indomethacin had no influence on the enzyme activity of the newly induced COX-2. However, both drugs in low concentrations were able to blunt the long term activation process resulting in PGE2 generation. In contrast, the prostaglandins generated by constitutive enzymes (COX-1) are probably involved in maintaining vital functions, and their inhibition by indomethacin and other nonsteroidal antiinflammatory drugs (NSAIDs) account for numerous adverse effects, for instance gastric erosion. Our study revealed that leflunomide and A 77 1726 are not to be regarded as COX-1-inhibitors, and thus cannot be associated with the typical adverse effects of the NSAIDs.
Similar articles
- A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.
Hamilton LC, Vojnovic I, Warner TD. Hamilton LC, et al. Br J Pharmacol. 1999 Aug;127(7):1589-96. doi: 10.1038/sj.bjp.0702708. Br J Pharmacol. 1999. PMID: 10455314 Free PMC article. - Effects of non-steroidal anti-inflammatory drugs on prostaglandin E2 production by cyclooxygenase-2 from endogenous and exogenous arachidonic acid in rat peritoneal macrophages stimulated with lipopolysaccharide.
Nakatsugi S, Sugimoto N, Furukawa M. Nakatsugi S, et al. Prostaglandins Leukot Essent Fatty Acids. 1996 Dec;55(6):451-7. doi: 10.1016/s0952-3278(96)90130-1. Prostaglandins Leukot Essent Fatty Acids. 1996. PMID: 9014225 - Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
Carty TJ, Sweeney FJ, Griffiths RJ, Eskra JD, Ernest MJ, Pillar JS, Cheng JD, Loose LD, Joseph PA, Pazoles PP, Moore PF, Nagahisa A, Murase S, Kadin SB. Carty TJ, et al. Inflamm Res. 1997 May;46(5):168-79. doi: 10.1007/s000110050163. Inflamm Res. 1997. PMID: 9197987 - The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes.
Burger D, Begué-Pastor N, Benavent S, Gruaz L, Kaufmann MT, Chicheportiche R, Dayer JM. Burger D, et al. Rheumatology (Oxford). 2003 Jan;42(1):89-96. doi: 10.1093/rheumatology/keg038. Rheumatology (Oxford). 2003. PMID: 12509619 - Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A, Ottani A, Sandrini M. Bertolini A, et al. Pharmacol Res. 2001 Dec;44(6):437-50. doi: 10.1006/phrs.2001.0872. Pharmacol Res. 2001. PMID: 11735348 Review.
Cited by
- Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review.
Alamri RD, Elmeligy MA, Albalawi GA, Alquayr SM, Alsubhi SS, El-Ghaiesh SH. Alamri RD, et al. Int Immunopharmacol. 2021 Apr;93:107398. doi: 10.1016/j.intimp.2021.107398. Epub 2021 Feb 8. Int Immunopharmacol. 2021. PMID: 33571819 Free PMC article. Review. - Total nutritional capacity and inflammation inhibition effect of Acalypha alnifolia Klein ex wild-An unexplored wild leafy vegetable.
Ponnusamy R, Thangaraj P. Ponnusamy R, et al. J Food Drug Anal. 2014 Dec;22(4):439-447. doi: 10.1016/j.jfda.2014.04.004. Epub 2014 Oct 29. J Food Drug Anal. 2014. PMID: 28911458 Free PMC article. - Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.
Alcorn N, Saunders S, Madhok R. Alcorn N, et al. Drug Saf. 2009;32(12):1123-34. doi: 10.2165/11316650-000000000-00000. Drug Saf. 2009. PMID: 19916579 Review. - Cyclooxygenase-2 and its regulation in inflammation.
Bakhle YS, Botting RM. Bakhle YS, et al. Mediators Inflamm. 1996;5(5):305-23. doi: 10.1155/S0962935196000452. Mediators Inflamm. 1996. PMID: 18475724 Free PMC article. No abstract available. - Anti-inflammatory effects of leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients.
Cutolo M, Capellino S, Montagna P, Sulli A, Seriolo B, Villaggio B. Cutolo M, et al. Ann Rheum Dis. 2006 Jun;65(6):728-35. doi: 10.1136/ard.2005.045641. Epub 2005 Nov 3. Ann Rheum Dis. 2006. PMID: 16269423 Free PMC article.
References
- Prostaglandins Leukot Med. 1984 Jan;13(1):53-60 - PubMed
- J Biol Chem. 1992 Dec 25;267(36):25934-8 - PubMed
- Prostaglandins Leukot Med. 1984 Apr;14(1):15-24 - PubMed
- Gastroenterology. 1981 Jan;80(1):94-8 - PubMed
- Proc Natl Acad Sci U S A. 1979 May;76(5):2148-52 - PubMed
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous